ÁñÁ«ÊÓƵ

This phase 1 randomized study assesses the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and its effects on serum concentrations of lipoprotein(a), in healthy participants and patients with stable atherosclerotic cardiovascular disease.

This randomized clinical trial compares a single dose of lepodisiran vs placebo to assess the safety, tolerability, pharmacokinetics, and effects on lipoprotein(a) concentrations in adults without cardiovascular disease and with lipoprotein(a) serum concentrations of 75 nmol/L or greater at baseline.

This randomized clinical trial investigates the long-term efficacy of mavacamten in reducing the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy.

This phase 1 study evaluated the safety and tolerability of 4 different doses of a short interfering RNA designed to reduce hepatic production of apolipoprotein(a) and assessed associated changes in plasma concentrations of lipoprotein(a), compared with placebo, among individuals with elevated lipoprotein(a) levels and no known cardiovascular disease.

This secondary analysis of a randomized clinical trial investigates the association between plasma levels of eicosapentaenoic acid and docosahexaenoic acid and cardiovascular outcomes in a trial of ω-3 fatty acids compared with corn oil placebo.

This randomized clinical trial examines whether high-dose zinc and/or high-dose ascorbic acid reduces the severity or duration of symptoms compared with usual care among ambulatory patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

This randomized trial examines the effects on cardiovascular outcomes of a carboxylic acid formulation of EPA and DHA (omega-3 CA) with documented favorable effects on lipid and inflammatory markers in patients with atherogenic dyslipidemia and high cardiovascular risk.

This secondary analysis of the randomized clinical ACCELERATE trial examines whether lipoprotein(a)-associated cardiovascular risk is modulated by systemic inflammation in optimally treated patients at high risk for cardiovascular disease.

This randomized clinical trial explores the effect of infusions of the high-density lipoprotein mimetic MDCO-216 on reducing the burden of coronary atherosclerosis in statin-treated patients with acute coronary syndrome in Canada and Europe.

This study explores whether the association between an SNP in the ADCY9 gene and a reduction in major adverse cardiovascular events could be replicated for another cholesteryl ester transfer protein inhibitor, evacetrapib, in patients with high-risk vascular disease.

This cohort study examines weight loss outcomes from surgical and nonsurgical interventions among patients with obesity before and after the COVID-19 outbreak.

This matched-cohort study uses Cleveland Clinic Health System data to investigate the association between bariatric surgery and major adverse cardiovascular events (MACE), including mortality, coronary disease and stroke, in adult patients with type 2 diabetes and obesity.